| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer D Cunningham, WH Allum, SP Stenning, JN Thompson, ... New England Journal of Medicine 355 (1), 11-20, 2006 | 7409 | 2006 |
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ... New England journal of medicine 351 (4), 337-345, 2004 | 6501 | 2004 |
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer J Valle, H Wasan, DH Palmer, D Cunningham, A Anthoney, A Maraveyas, ... New England Journal of Medicine 362 (14), 1273-1281, 2010 | 4220 | 2010 |
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial JY Douillard, D Cunningham, AD Roth, M Navarro, RD James, P Karasek, ... The Lancet 355 (9209), 1041-1047, 2000 | 4141 | 2000 |
| Capecitabine and oxaliplatin for advanced esophagogastric cancer D Cunningham, N Starling, S Rao, T Iveson, M Nicolson, F Coxon, ... New England Journal of Medicine 358 (1), 36-46, 2008 | 2735 | 2008 |
| Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2581 | 2013 |
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a … H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ... The lancet oncology 15 (11), 1224-1235, 2014 | 2457 | 2014 |
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS … E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ... J Clin Oncol 29 (15), 2011-2019, 2011 | 2314 | 2011 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 2211 | 2010 |
| A prognostic score for advanced Hodgkin's disease D Hasenclever, V Diehl, JO Armitage, D Assouline, M Björkholm, ... New England Journal of Medicine 339 (21), 1506-1514, 1998 | 2199 | 1998 |
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised … JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, ... The Lancet 389 (10073), 1011-1024, 2017 | 1859 | 2017 |
| Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EC Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold Annals of oncology 27, v38-v49, 2016 | 1653 | 2016 |
| Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JP Neoptolemos, DD Stocken, C Bassi, P Ghaneh, D Cunningham, ... Jama 304 (10), 1073-1081, 2010 | 1620 | 2010 |
| Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer D Cunningham, S Pyrhönen, RD James, CJA Punt, TF Hickish, R Heikkila, ... The Lancet 352 (9138), 1413-1418, 1998 | 1573 | 1998 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1479 | 2018 |
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial AD Roth, S Tejpar, M Delorenzi, P Yan, R Fiocca, D Klingbiel, D Dietrich, ... J Clin Oncol 28 (3), 466-474, 2010 | 1431 | 2010 |
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R Marcus, K Imrie, A Belch, D Cunningham, E Flores, J Catalano, ... Blood 105 (4), 1417-1423, 2005 | 1238 | 2005 |
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, ... Journal of Clinical Oncology 15 (1), 261-267, 1997 | 1161 | 1997 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1156 | 2016 |
| Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? HJN Andreyev, AR Norman, J Oates, D Cunningham European journal of cancer 34 (4), 503-509, 1998 | 1131 | 1998 |
